Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intezyne, Inc.
Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
- Other Names / Subsidiaries
- Niiki Pharma, Inc